Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2016 February;64(1) > Minerva Cardioangiologica 2016 February;64(1):9-14



To subscribe PROMO
Submit an article
Recommend to your librarian


Cite this article as



Minerva Cardioangiologica 2016 February;64(1):9-14


language: English

Clinical performance of biodegradable polymer-coated sirolimus-eluting stents in unselected real-world population with coronary artery disease: results from the multicenter CORE Registry

Darshan BANKER 1, Anand AHUJA 1, Harish SANADHYA 2, Chandra PUROHIT 2, Sharad CHANDRA 3, Rishi SETHI 3, Rashi KHARE 3, Shivani KOTHARI 4, Ashok THAKKAR 4

1 Banker Heart Institute, Vadodara, India; 2 Geetanjali Cardiac Center, Geetanjali Hospital, Udaipur, India; 3 Department of Cardiology, King George’s Medical University, Uttar Pradesh, India; 4 Department of Clinical Trials, Sahajanand Medical Technologies Pvt. Ltd., Surat, India


BACKGROUND: The main aim of the CORE Registry was to evaluate clinical performance of the Supralimus-Core® biodegradable polymer-coated sirolimus-eluting cobalt-chromium stent (Sahajanand Medical technologies Pvt. Ltd., Surat, India) in unselected real-world patients.
METHODS: This was a multicenter, retrospective, non-randomized, single-arm study. A total of 376 consecutive patients treated with the Supralimus-Core® between April 2010 and June 2014 were enrolled. The primary-end point of the registry was major adverse cardiac events (MACE), which is a composite of cardiac death, target lesion revascularization (TLR), target vessel revascularization (TVR), myocardial infarction (MI) and stent thrombosis (ST). Clinical follow-up were scheduled at 30-day and 6-month.
RESULTS: The mean age of enrolled patients was 54.6±10.3 years. A total of 444 lesions were treated successfully with 457 stents (1.0±0.2 per lesion). The average stent length and diameter was 24.0±8.0 mm and 3.0±0.33 mm, respectively. Out of total patients, 300 (79.8%) were male. Diabetes, hypertension and chronic totally occluded lesions were found in 95 (25.3%), 102 (27.1%) and 125 (28.2%) patients, respectively, reflecting high-risk patients involvement. The incidence of MACE at 30-day and 6-month was found to be in 4 (1.1 %) and 4 (1.1%) patients, respectively. The TLR and ST was found in 1 (0.3 %) and 1 (0.3 %) patient respectively at 6-month follow-up.
CONCLUSIONS: The lower incidence of MACE, TLR and ST clearly delineates safety and efficacy of Supralimus-Core sirolimus-eluting stent in “real-world” patients with complex coronary lesions.

top of page